Holen Sie sich die Stockscreener-App
21.66
8.30%
1.66
Vorhandelsmarkt:
21.31
-0.35
-1.62%
Schlusskurs vom Vortag:
$20.00
Offen:
$20.2
24-Stunden-Volumen:
293.85K
Relative Volume:
1.17
Marktkapitalisierung:
$641.07M
Einnahmen:
$4.12M
Nettoeinkommen (Verlust:
$-56.68M
KGV:
-3.9077
EPS:
-5.5429
Netto-Cashflow:
$-51.44M
1W Leistung:
+8.98%
1M Leistung:
-8.99%
6M Leistung:
-18.45%
1J Leistung:
+81.26%
1-Tages-Spanne:
$19.82
$21.77
1-Wochen-Bereich:
$18.34
$21.77
52-Wochen-Spanne:
$13.59
$33.77
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
857-201-2700
Adresse
300 TECHNOLOGY SQUARE, CAMBRIDGE
Vergleichen Sie DNTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
21.66 | 641.07M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Analysts - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short Interest - MarketBeat
A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5%Here's Why - MarketBeat
Barclays PLC Purchases 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Barclays PLC Acquires 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Dianthus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.8%Should You Sell? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 7.8%Here's What Happened - MarketBeat
Jane Street Group LLC Takes $556,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stake Trimmed by Geode Capital Management LLC - Defense World
Barclays PLC Boosts Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Position Raised by Barclays PLC - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Brokerages - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 2.5%Here's Why - MarketBeat
State Street Corp Increases Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
State Street Corp Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
TD Cowen Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Now Covered by TD Cowen - MarketBeat
Wellington Management Group LLP Invests $1.47 Million in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded at Raymond James - Defense World
Raymond James Upgrades Dianthus Therapeutics (NASDAQ:DNTH) to Moderate Buy - MarketBeat
Charles Schwab Investment Management Inc. Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Charles Schwab Investment Management Inc. Boosts Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
MetLife Investment Management LLC Purchases 7,854 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Point72 Asset Management L.P. Buys 263,500 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Janus Henderson Group PLC Acquires 273,670 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
30,000 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Acquired by Walleye Capital LLC - MarketBeat
HighVista Strategies LLC Purchases New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asia Singapore Pte. Ltd. - MarketBeat
Avidity Partners Management LP Increases Stake in Dianthus Thera - GuruFocus.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Quest Partners LLC Has $31,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Braidwell LP Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Vestal Point Capital LP - MarketBeat
Great Point Partners LLC Lowers Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5.1%What's Next? - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates - MSN
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1%Should You Sell? - MarketBeat
What is HC Wainwright's Estimate for DNTH FY2024 Earnings? - MarketBeat
Raymond James Forecasts Strong Price Appreciation for Dianthus Therapeutics (NASDAQ:DNTH) Stock - Defense World
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts - Benzinga
Dianthus Therapeutics' (DNTH) Buy Rating Reiterated at HC Wainwright - MarketBeat
Oppenheimer Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
Dianthus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up After Analyst Upgrade - Defense World
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):